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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with no cure, and elucidation of the mechanisms
mediating neuronal death in this neuropathology is crucial to develop effective treatments. It has recently been demonstrated
in animal models that the Wnt family of proteins is involved in this neuropathology, although its potential involvement in case of
humans is almost unknown.We analyzed the expression ofWnt signaling components in healthy andALS human spinal cords by
quantitative RT-PCR, and we found that most Wnt ligands, modulators, receptors, and co-receptors were expressed in healthy
controls. Moreover, we observed clear alterations in the mRNA expression of different components of this family of proteins in
human spinal cord tissue from ALS cases. Specifically, we detected a significant increase in the mRNA levels of Wnt3, Wnt4,
Fz2, and Fz8, together with several non-significant increases in the mRNA expression of other genes such asWnt2b,Wnt5a, Fz3,
Lrp5, and sFRP3. Based on these observations and on previous reports of studies performed in animal models, we evaluated with
immunohistochemistry the protein expression patterns of Fz2 and Fz5 receptors and their main ligand Wnt5a in control samples
and ALS cases. No substantial changes were observed in Fz5 protein expression pattern in ALS samples. However, we detected
an increase in the amount of Fz2+ astrocytes in the borderline between gray and white matter at the ventral horn in ALS samples.
Finally, Wnt5a expression was observed in neurons and astrocytes in both control and ALS samples, although Wnt5a
immunolabeling in astroglial cells was significantly increased in ALS spinal cords in the same region where changes in Fz2
were observed. Altogether, these observations strongly suggest that the Wnt family of proteins, and more specifically Fz2 and
Wnt5a, might be involved in human ALS pathology.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common mo-
toneuron (MN) disease in human adults, with a worldwide
incidence of two or three cases per year and per 100,000
population [1, 2]. The degeneration affects MNs in the brain,
brainstem, and spinal cord, resulting in progressive weakness
and atrophy of voluntary skeletal muscles and eventually lead-
ing to death due to respiratory failure within 3 to 5 years from
diagnosis [2–5]. Approximately 90% of ALS cases have an
unknown etiology and are classified as sporadic, while nearly
10% are inherited or familiar, although the two forms are
clinically indistinguishable and probably share common dis-
ease mechanisms [6, 7]. Unfortunately, to date, the only drug
approved to treat ALS, Riluzole, has a modest effect in
prolonging survival [8, 9]. One of the major handicaps in the
generation of effective treatments for this fatal neurodegener-
ative disease is that the causes of ALS remain largely un-
known, mainly due to poor understanding of the specific
mechanisms that lead to the development of the disease [10,
11]. These pathophysiological mechanisms are likely to be the
result of a complex interplay between several dysregulated
processes, including RNA processing abnormalities,
excitotoxicity, protein aggregation, defective axonal transport,
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oxidative stress, mitochondrial dysfunction, apoptosis, neuro-
inflammation and activation, and proliferation of astrocytes
and microglia [12–14]. Another major handicap in developing
new therapies is the lack of direct translation from preclinical
findings to a successful clinical outcome, mainly because of
the incomplete phenotypes of the models and the absence of
treatment reproducibility in humans [6, 15]. Therefore, it is
critical not only to elucidate the molecular and cellular mech-
anisms involved in ALS in clinically relevant experimental
models but also to corroborate their potential existence and
relevance in humans.
Interestingly, recent studies carried out in animal models
have shown that the Wnt family of proteins, a well-known
regulator of crucial processes in the developing [16–18] and
adult [18–20] central nervous system (CNS) under physiolog-
ical conditions, is also clearly involved in many of the cellular
and molecular processes that characterize the progression and
outcome of different CNS pathologies [21–28]. Notably, re-
cent studies have described a dysregulation in the expression
of several members of this family of proteins in the spinal cord
of a mouse model of ALS and also in an in vitro model of the
disease [29–37]. However, despite these interesting observa-
tions pointing to a relevant function of the Wnt family of
proteins in the progression of ALS in experimental models,
there is a complete lack of information about its potential role
in human ALS. Briefly, this family of proteins is composed of
19Wnt ligands (Wnt1, 2, 2b, 3, 3a, 4, 5a, 5b, 6, 7a, 7b, 8a, 8b,
9a, 9b, 10a, 10b, 11, and 16), 10 Frizzled (Fz) receptors (Fz1–
10), the LRP-5/6 co-receptors, and other non-conventional
receptors such as the receptor-like tyrosine kinase (Ryk), the
receptor tyrosine kinase-like orphan receptor (ROR) 1/2, and
the protein tyrosine kinase 7 (PTK7) [38–42]. Classically,
Wnt signaling has been divided into canonical and non-
canonical pathways. The canonical controls target gene tran-
scription through the β-catenin protein, which functions as a
transcriptional co-activator upon entering the nucleus. The
non-canonical pathways are β-catenin-independent and are
known as planar cell polarity and Wnt/Ca2+ pathways
[43–45]. All these signaling pathways are finely regulated at
different levels by a wide range of regulatory molecules which
includes different extracellular antagonists such as secreted
Frizzled-related proteins (sFRP) 1–5, Dickkopf (Dkk) 1–4,
and the Wnt inhibitory factor 1 (Wif1) [42, 46, 47].
As a first essential step to achieve a better understanding of
the potential implication of the dysregulation of the Wnt fam-
ily of proteins in the pathogenesis of human ALS, we aimed
here to study for the first time the potential existence of alter-
ations in the mRNA expression of the different components of
the Wnt family of proteins in the spinal cord from ALS cases.
Moreover and based on the results obtained and on previous
reports, we analyzed, in human spinal cord samples, whether
the ALS pathology correlates with changes in the protein ex-
pression and spatial distribution of Fz5, as we have previously
shown in a mouse model of ALS [37], and also of Fz2 and
Wnt5a, since it has been recently described that the expression
of these two molecules is found altered in a mouse model of
ALS [30].
Materials and Methods
Human Spinal Cord Samples
Human postmortem tissue samples of cervical, thoracic,
and lumbar spinal cord levels were obtained from the
HUB-ICO-IDIBELL Biobank (see Table 1 for detailed
information about the human spinal cord samples used).
Table 1 Summary of human spinal cord samples used for the present
study. The table shows data from human spinal cord samples obtained
from control individuals (no histopathological affectation in the spinal
cord) and amyotrophic lateral sclerosis (ALS) cases, and whether they
were used for RT-PCR experiments, immunofluorescence (IF) or both. F:
female; M: male; h: hours
Case Age Gender Diagnosis Postmortem delay IF PCR
1 64 M Control 10 h 40 min X
2 65 M Control 05 h 15 min X
3 56 M Control 07 h 10 min X
4 71 F Control 08 h 30 min X X
5 64 F Control 05 h 00 min X X
6 79 F Control 06 h 25 min X
7 63 M Control 03 h 50 min X
8 50 M Control 17 h 15 min X
9 76 M Control 06 h 30 min X
10 60 F Control 11 h 30 min X
11 47 M Control 10 h 25 min X
12 59 M Control 08 h 30 min X
13 51 F Control 04 h 00 min X X
14 54 F Control 08 h 00 min X
15 70 M ALS 03 h 00 min X
16 59 M ALS 03 h 15 min X
17 67 M ALS 11 h 45 min X
18 63 F ALS 13 h 50 min X
19 71 M ALS 08 h 45 min X
20 57 M ALS 04 h 00 min X X
21 75 F ALS 04 h 05 min X X
22 79 F ALS 02 h 10 min X
23 57 F ALS 10 h 00 min X
24 50 M ALS 10 h 10 min X
25 75 M ALS 03 h 00 min X
26 71 M ALS 03 h 15 min X
27 59 F ALS 02 h 30 min X
28 46 M ALS 07 h 00 min X X
29 68 F ALS 07 h 00 min X
Mol Neurobiol
All individuals or relatives had given their written in-
formed consent. Data from donors and handling of sam-
ples were carried out after approval by the Clinical
Research Ethical Committee (CEIC) in Toledo (Spain)
and in accordance with Spanish law and International
Guidelines (LOPD 15/1999; RD 1720/2007; Helsinki
declaration, 2008). Patients with associated pathology
including Alzheimer’s disease (excepting neurofibrillary
tangle pathology stages I–II of Braak and Braak [48,
49], Parkinson’s disease, tauopathies, vascular diseases,
neoplastic diseases affecting the nervous system, meta-
bolic syndrome, hypoxia and prolonged axonal states
such as those occurring in intensive care units were
excluded. Cases with infectious, inflammatory, and au-
toimmune diseases, either systemic or limited to the
nervous system, were not included. Age-matched control
cases had not suffered from neurologic or psychiatric
diseases and did not have abnormalities in the neuro-
pathologic examination, excepting sporadic neurofibril-
lary tangle pathology I–II of Braak categorization
stages. No C9ORF72, SOD1, TARDBP and FUS muta-
tions occurred in any case.
RNA Extraction and Purification
As the severe atrophy in the anterior horns of the spinal cord,
with strong neuronal loss and microglia and astroglia activa-
tion, is one of the main characteristics of ALS [12, 50], we
focused our studies on this region. RNA extraction from fro-
zen anterior horns of the spinal cord (n = 6 controls and n = 6
ALS cases) was performed with RNeasy Lipid Tissue Mini
Kit (Qiagen, Hilden, DE) following instructions provided by
the supplier and performing the optional DNase digest to
avoid extraction and later amplification of genomic DNA.
The concentration of each sample was measured at 340 nm
with the NanoDrop, and 2 μg of total RNA per sample was
reverse-transcribed as described [22].
Gene Expression Assays
To test the mRNA expression of the Wnt family members, we
used customized Taq-Man Array Microfluidic Cards
(4342253, Applied Biosystems) previously used and validated
in a recent study performed by our group [20], the TaqMan
Gene Expression Master Mix (4369016, Applied
Biosystems), and 20 ng of total reverse-transcribed RNA per
well. Based on our previous data [20] and the manufacturer’s
technical recommendations, we chose 18S gene as endoge-
nous control . All react ions were run on an ABI
PRISM7900HT Fast Sequence Detection System (Applied
Biosystems), and cycle threshold (Ct) > 35 was considered
as undetectable.
Single and Double Immunofluorescence, Confocal
Microscopy, and Image Analysis
Formalin-fixed, paraffin-embedded tissue sections of 4–
5 μm thick from controls (n = 11) and ALS cases (n =
12) were dewaxed, rehydrated, and processed for immu-
nofluorescence assays. Briefly, the sections were sub-
jected to heat-induced antigen retrieval treatment,
consisting of a 30-min pretreatment with a 0.05% solu-
tion of citraconic anhydride (Sigma, #27430) at 96 °C,
followed by temperature re-accommodation at room
temperature (RT) for at least 45 additional minutes
[51]. Next, sections were extensively washed with
0.1 M TBS (pH 7.4) plus 0.1% Triton X-100 and then
blocked for 1 h at RT with 10% fetal bovine serum and
0.3% bovine serum albumin diluted in TBS. The subse-
quent experimental protocol used has previously been
described [22]. The following primary antibodies were
used: rabbit anti-Fz2 (1:100; Abcam, ab94913), rabbit
anti-Fz5 (1:100; Abcam, ab75234), rabbit anti-Wnt5a
(1:50; Abcam, ab174963), mouse anti-glial fibrillary
acidic protein (GFAP) (1:500; Sigma, G3893), mouse
anti-Neuro-Chrom™ Pan Neuronal (1:50; Millipore,
MAB2300), and goat anti-ionized calcium binding adap-
tor protein 1 (Iba1) (1:100; Abcam, ab5076). Thereafter,
the corresponding Dylight488-linked anti-mouse (1:500;
Vector Laboratories, DI-2488), Dylight594-linked anti-
rabbit (1:500; Vector Laboratories, DI-1594), and
Alexa488-linked anti-goat (1:1000; Life technologies,
A11055) secondary antibodies were used. To reduce tis-
sue autofluorescence, sections were treated with Sudan
black as previously described [52]. Briefly, at the end of
the immunohistochemical procedure, the slides were im-
mersed for 5 min at RT in a filtered solution of 0.5%
Sudan black (Sigma, S2380) diluted in 70% ethanol.
Finally, different controls were carried out to confirm
a lack of undesired non-specific immunohistochemical
staining. Briefly, to ensure the specificity of the primary
antibodies used to visualize Fz2, Fz5, and Wnt5a, we
pre-incubated these antibodies, following the protocol
previously described [53], with their corresponding
blocking peptides belonging to human Fz2 (Abcam,
ab234541), Fz5 (Abcam, ab234542), and Wnt5a
(Abcam, ab239129). Pre-incubation of the antibodies
with their corresponding blocking peptides was per-
formed with 10-fold weight/weight excess for Fz2 and
5 and with 20-fold weight/weight excess for Wnt5a. As
shown (Fig. S1), antibody pre-incubation completely
abolished Fz2 and 5 immunostaining, while in the case
of Wnt5a, only a faint punctuate staining was observed
in a thin area of subpial white matter. Moreover, to
confirm a lack of undesired cross-reactivity of the dif-
ferent secondary antibodies used, both sections
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processed without the primary antibodies and sections
processed without the second primary antibody were
used as controls. Again, no non-specific staining was
observed.
Qualitative microscopic evaluation of Fz2, Fz5, and
Wnt5a immunoreactivity was made using a BX61
Motorized Research Microscope (Olympus), and high
magnification images were acquired with a Leica TCS
SP5 confocal microscope (Leica Microsystems).
Quanti tat ive image analysis was carried out in
GFAP/Wnt5a composite × 40 images that were taken in
the ventral horns from sections processed with Wnt5a/
GFAP double immunohistochemistry using a Leica TCS
SP5 resonant scanner confocal microscope (Leica
Microsystems). The same acquisition settings were used
to obtain GFAP, or Wnt5a images in all sample image
analysis was accomplished in a blinded manner using the
Fiji software [54]. In each image, a square region of
interest (ROI) of 0.2 mm2 was selected in the ventral
horn region, just below the transition between the GM
and the WM of the anterior funiculi, where qualitative
changes in Wnt5a expression were observed. The ROI
analyzed represents between 6 and 19% of the total area
of the ventral horn, depending on the spinal cord level in
each case. Subsequently, the single confocal plane show-
ing the maximum immunohistochemical signal was se-
lected in each ROI. A threshold was then established to
specifically detect and quantify the area occupied by
Wnt5a or GFAP staining. The selected thresholds were
maintained in all analyzed images. To quantify the over-
lapping area between Wnt5a and GFAP in the same pre-
viously selected ROI and confocal planes, we followed
an already described protocol with slight modifications
[55]. More specifically, we outlined GFAP immunostain-
ing with the previously determined thresholds and used
this selected region on the corresponding Wnt5a images
to calculate the Wnt5a+/GFAP+ area in each image. A
total of two to six sections of the ventral horn were
analyzed in each sample, and data were averaged to ob-
tain a single value per subject.
Statistical Analysis
PCR Analysis
After averaging Cts from technical duplicates, we calculated
ΔCt value in each sample (the difference between the Ct of
each gene and the Ct of the housekeeping gene (18S)), and the
existence of statistically significant differences between con-
trol and ALS cases in ΔCt values was determined with two-
tailed unpaired Student’s t test with statistical significance set
at p < 0.05. Data are expressed as the 2−ΔΔCT mean ± SEM.
Statistical analyses were performed using GraphPad Prism
(version 6.01).
Quantitative Immunofluorescence Analysis
The existence of significant differences between controls and
ALS cases in GFAP+, Wnt5a+, and Wnt5a/GFAP+ areas was
assessed with two-tailed unpaired Student’s t test with statis-
tical significance set at p < 0.05. Data are expressed as the
mean ± SEM. Statistical analyses were again performed using
GraphPad Prism (version 6.01).
Results
Gene Expression Dysregulation of the Wnt Family
of Proteins in Spinal Cord of ALS Cases
Evaluation of the mRNA expression of Wnt-related genes in
the anterior horn of the spinal cord of controls and ALS cases
demonstrates that, under both normal and pathological condi-
tions, most Wnt ligands (Wnt2, 2b, 3, 4, 5a, 5b, 6, 7a, 7b, 8a,
8b, 9b, 10a, 10b, 11, and 16), receptors (Fz1–10), co-receptors
(Lrp5–6), non-conventional receptors (Ror1–2, Ptk7, and
Ryk), and modulators (Dkk1–4, sFRP1–5, and Wif1) were
expressed in the adult human spinal cord (Fig. 1). We found
only undetectable mRNA expression levels of Wnt1, Wnt3a,
and Wnt9a ligands. Moreover, we observed that ALS was
associated with a clear dysregulation of the mRNA expression
of several Wnt family members. Specifically, the mRNA ex-
pression ofWnt3 andWnt4 ligands and Fz2 and Fz8 receptors
was significantly increased, while the mRNA levels ofWnt2b,
Wnt5a, Fz3, Lrp5, and sFRP3 showed an interesting non-
significant increase in ALS patients (Fig. 1).
Cellular and Spatial Distribution Variations of Fz2
and Absence of Changes of Fz5 in Spinal Cord of ALS
Cases
We next assessed whether the changes in mRNA expression
detailed above were reflected at the protein level or whether
ALS correlates with potential alterations in the spatial and/or
cellular distribution of some of these molecules. Firstly, we
focused on the Fz2 receptor, as it is the Wnt-related molecule
that suffered the most significative change at the mRNA level
in ALS cases, and recent studies have shown that its expres-
sion is increased in the spinal cord of ALS transgenic mice,
specifically in astrocytes [30]. Moreover, we also analyzed the
protein expression pattern of Fz5 receptor, since we recently
demonstrated that its spatial and cellular expression pattern
showed evident alterations in the SOD1G93A transgenicmouse
model of ALS, even though at the mRNA level no differences
were found [37]. Figure 2 shows representative images of the
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results obtained from the qualitative microscopic analysis of
the spatial distribution of these two receptors. Again, we fo-
cused these analyses on the anterior horn of the spinal cord,
which is one of the main affected areas in ALS and the specific
region where we evaluated the mRNA expression of these
molecules.
In the control healthy spinal cords, Fz2 receptor
immunolabeling was mainly observed in the GM in cells
displaying a neuronal-like profile, and in highly ramified cells
and cellular processes mostly in the WM close to the pial
surface (not shown), and to a lesser extent in the WM sur-
rounding the GM at the ventral horn (Fig. 2a, b).
Fig. 1 Gene expression pattern alterations of different members involved
in Wnt signaling pathways in the adult human spinal cord of healthy
(control) and ALS cases. Almost all ligands, Fz receptors, co-receptors,
unconventional receptors, and more characteristic extracellular inhibitors
and modulators were detected in the ventral horn of healthy and ALS
human spinal cord. Significant overexpression associated with ALS was
found for Wnt3, Wnt4, Fz2, and Fz8 genes, together with several
increasing tendencies that almost reached significance for Wnt2b,
Wnt5a, Fz3, Lrp5, and sFRP3 genes. Data are presented as fold change
compared to control group and represent the mean ± SEM. *p < 0.05;
***p < 0.001
Fig. 2 Expression and
distribution of Fz2 and Fz5
receptors in healthy (control)
human spinal cord and ALS
cases. Representative images
showing the distribution of Fz2
and Fz5 receptors in the ventral
horn region of the spinal cord in
controls (a–c) and ALS cases (d–
f). Both receptors showed
immunoreactivity in cells with a
MN profile that disappeared
concomitant to the cellular death
process. No more changes were
detected for Fz5 receptor, while
an increase in Fz2+ glial profiles
was observed associated with
ALS in the ventral horn of the
spinal cord. The discontinuous
line marks the boundary between
the gray matter (GM) and the




Conversely, in spinal cord samples from ALS cases, we
found an evident increase in the amount of Fz2+ cellular
processes and ramified cells in the WM bordering the
GM in the ventral horn and, to a lesser extent, in the
ventral horn GM (Fig. 2d, e). Concomitantly, an almost
complete disappearance of Fz2+ cells displaying a
neuronal-like profile was also observed, probably due
to the death of ventral horn neurons that takes place
during the progression of this neuropathology (Fig.
2d, e). Interestingly, the increase in the amount of Fz2+
ramified cells in the previously detailed areas was more
evident in those ALS samples that displayed a lower
number of preserved MNs.
In contrast, we did not observe evident qualitative var-
iations in the spatial expression pattern of Fz5. More spe-
cifically, Fz5 expression was clearly found in cells with a
neuronal-like profile in the GM of the ventral horn of
healthy spinal cords (Fig. 2c). In spinal cord samples from
ALS cases, the expression pattern of Fz5 was very similar.
Only a reduction of Fz5 signal was observed in this re-
gion (Fig. 2f), but once again probably due to the associ-
ated neuronal death, and not as a consequence of the loss
of Fz5 receptor expression.
Cellular Expression Pattern of Fz2 Receptor in Healthy
and ALS Human Spinal Cord
Based on the observations described above, we next
characterized the cell types that expressed Fz2 receptor,
specifically focusing on crucial cells implicated in this
pathology: neurons, astrocytes, and microglia [56, 57].
In both healthy and ALS spinal cords, Fz2 receptor was
expressed in neurons and astrocytes (Fig. 3, a1–a2, b1–
b2), but not in microglial cells (Fig. 3, a3, b3). However,
we found that the increment in Fz2 immunolabeling
observed in the ventral horn region in ALS spinal cords
was due to an increase in the amount of Fz2-expressing
astrocytes (Fig. 3, b1). Finally, we also observed that
the loss of Fz2 immunohistochemical signal in neurons
in ALS samples was probably associated with the death
of these cells, since in those neurons that remained
alive, we still observed the expression of this receptor
(Fig. 3, b2).
Cellular Expression Pattern of Wnt5a Ligand
in Healthy and ALS Human Spinal Cord
At this point, we decided to evaluate the cellular expression
pattern of Wnt5a as a potential Fz2 interacting ligand which,
as previously stated, showed a clear increasing trend in its
mRNA expression in spinal cord samples from ALS cases
(Fig. 1). Further, the same authors that have described Fz2
alterations in ALS mice showed that Wnt5a was also upregu-
lated in astrocytes of the transgenic mice [30]. Then, parallel
to Fz2 experiments, we focused our study on the same cell
types. We found that in both healthy and ALS spinal cords,
Wnt5a was expressed in astrocytes (Fig. 4, a1, b1) and neurons
(Fig. 4, a2, b2), but not in microglial cells (Fig. 4, a3, b3).
Moreover, we observed a qualitative increase in the amount
ofWnt5a-expressing astrocytes mostly in the region ofWM in
close contact with GM in the anterior horn of the ALS spinal
cord, where the changes in Fz2 protein expression pattern
were found (Fig. 5a–f).
Upregulation of Wnt5a Protein in the Spinal Cord
of ALS Cases
We subsequently quantified Wnt5a immunolabeling in
astroglial cells, in the same region where the qualitative
changes were found (Fig. 5a–f), to infer whether ALS corre-
lates with changes in Wnt5a expression in this cell types and
thus corroborate the previously detailed qualitative observa-
tions. Firstly, we found that Wnt5a+ area was significantly
higher in ALS cases than in controls (Fig. 5g) strongly sug-
gesting that, in accordance with the results obtained at the
mRNA level, the expression of this Wnt ligand is also in-
creased at the protein level. Secondly, we also observed that
ALS led to an increase in GFAP+ area in this region (Fig. 5h),
pointing to the activation of astroglial cells as previously de-
scribed in ALS patients [58, 59]. Next, we found that in ALS
spinal cords there was a significant increase in Wnt5a+/
GFAP+ area in this region (Fig. 5i), strongly indicating that
ALS is associated with an increment in the astroglial expres-
sion of Wnt5a and that this increment is, at least in part, con-
tributing to the increase observed inWnt5a expression in ALS
samples.
Discussion
ALS is a progressive neurodegenerative disease, described in
1869 by Jean-Martin Charcot, characterized byMN loss in the
spinal cord, brainstem, and motor cortex [2, 4, 12]. ALS has
been investigated for many years, and several studies have
shed some light on the different mechanisms underlying this
neuropathology, including impaired RNA metabolism, oxida-
tive stress, glutamate excitotoxicity, mitochondrial
Fig. 3 Cellular expression pattern of Fz2 receptor in healthy (control) and
ALS human spinal cord. Representative images showing the expression
of Fz2 by different cell types. In healthy controls, Fz2 was expressed by
astrocytes (a1) and neurons (a2), but not by microglial cells (a3). In ALS
cases, the Fz2+ cells with glial morphology that arise at ventral horn were
mostly astrocytes (b1). Moreover, Fz2 immunolabeling was still observed
in neurons (b2) in those individuals where neuronal cells were still
present, but not in microglia (b3). Squares in (a) and (b) indicate areas
where the different higher magnification micrographs were obtained.




dysfunction, protein aggregation, autophagic dysfunction,
neuroinflammation, and impaired axonal transport, among
others [14, 60]. Unfortunately, no effective treatments have
been identified yet to prevent or stop the neuronal death and
the progression of the disease. For these reasons, it is abso-
lutely crucial to study the different molecular mechanisms
underlying this neuropathology to achieve a better compre-
hension of ALS progression and unravel new potential thera-
peutic targets. In this line, recent studies have shown that the
Wnt family of proteins, which plays key roles during CNS
development [16–18] and adult homeostasis [18–20], is a crit-
ical factor involved in the progression of different neuropa-
thologies, such as Alzheimer’s disease [21, 28, 61],
Huntington’s disease [62, 63], Parkinson’s disease [64, 65],
multiple sclerosis [66, 67], glioma [68], spinal cord injury
[22–25, 69, 70], and ALS [29–37].
The bulk of the knowledge relative to Wnt signaling in-
volvement in the pathogenesis of ALS comes from SOD1
transgenic mouse models [30–37, 71, 72] and some in vitro
studies [29, 33, 71, 73]. Interestingly, these reports show al-
terations in the mRNA expression pattern of many Wnt sig-
naling components, including ligands, receptors, modulators,
and target genes in the spinal cord of ALS mice. Furthermore,
the authors describe alterations in protein levels and cellular
distribution of some Wnt molecules, as for instance, Fz1 and
Fig. 4 Cellular expression pattern of Wnt5a ligand in healthy (control)
and ALS human spinal cord. Representative images showing the
expression of Wnt5a by different cell types. In both healthy and ALS
samples, Wnt5a was located in astrocytes (a1 and b1) and neurons (a2
and b2) but not in microglial cells (a3 and b3). Squares in (a) and (b)
indicate areas where the different higher magnification micrographs were
obtained. Scale bars = 50 μm
Fig. 5 Quantification of Wnt5a immunolabeling in healthy and ALS
human spinal cord. Representative images (a–f) showing the region
where the quantitative analysis were performed and illustrative for the
alterations observed in astroglial Wnt5a expression. As shown, both
Wnt5a (g) and GFAP (h) immunolabeling were significantly increased
in ALS cases compared with healthy controls in this area. Moreover,
Wnt5a staining in astroglial cells was also significantly augmented in
ALS spinal cords (i). Data represent the mean ± SEM. *p < 0.05;
**p < 0.01. Scale bars = 100 μm
R
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Wnt1 [33]; Wnt4 and Wif1 [31]; Ryk [32]; Wnt2, Wnt7a, and
GSK3β [34]; Wnt3a, Cyclin D1, and β-catenin [35]; or Fz2
andWnt5a [30], in all cases focused on the anterior horn of the
mouse spinal cord and mainly related to astrocytes and MNs.
Surprisingly, only one study has been published linking Wnt
altered expression and ALS in humans, showing that the ex-
pression of Wnt1, 3a, 5a, 7a, and β-catenin suffered evident
changes in extraocular and limbmuscles of ALS subjects [36].
However, there is no information available about the existence
of potential alterations in the expression of the different com-
ponents of the Wnt family of proteins in the human CNS
during the progression of ALS. In this complex and novel
scenario, where our understanding of Wnt signaling
dysregulations and their potential contribution to human
ALS pathogenesis is scarce, we describe here for the first time
an altered expression of Wnt family proteins in human ALS
spinal cord.
Interestingly, the dysregulated expression of Wnt signaling
components observed in ALS human spinal cord resembles
mRNA alterations described in ALS mice spinal cord, in
which it has been shown that manyWnt ligands, Fz receptors,
endogenous antagonists, downstream effectors, and target
genes modify their expression during the progression of the
disease [30, 31, 33–35]. Although our analysis was focused on
the ventral horn region and data from these studies in mice
came from the analysis of the whole spinal cord section, we
observed similar alterations in both cases. Remarkably, Wnt2,
Wnt3, Wnt4, and specially Wnt5a ligands suffered a signifi-
cant increase in their expression at final stage of disease in
mice, as well as all Fz receptors and some modulators such as
sFRP3 or sFRP4 [31]. In agreement with this, we have iden-
tified several genes that were significantly upregulated, such
as Wnt3, Wnt4, Fz2, and Fz8, and other genes that showed an
interesting non-significant increase in their mRNA expres-
sion, such as Wnt2b, Wnt5a, Fz3, Lrp5, and sFRP3.
According to our results, both canonical and non-canonical
Wnt signaling molecules were upregulated in ALS human
spinal cord, and altogether, these observations point strongly
to the potential implication of theWnt family of proteins in the
pathogenesis of the disease in humans.
Then, we aimed to examine whether these changes in
mRNA expression were reflected at the protein level or
whether ALS was associated with spatial and/or cellular
distribution alterations of some of these molecules. As
discussed above, we focused on Fz2 receptor, which
seems to be the Wnt-related molecule that suffered the
clearest change at the mRNA level in ALS cases, and
also on Fz5, since we recently showed that its spatial
and cellular expression pattern was altered in the
SOD1G93A transgenic mouse model of ALS [37]. In
the healthy human, spinal cord Fz2 receptor was clearly
expressed in neurons in the ventral horns and astrocytes
mostly in the WM. In agreement with these results, we
and others have shown Fz2 expression in neurons and
astrocytes in the healthy adult rat [23] and mouse [30]
spinal cord, as well as in non-activated cultured brain
and spinal cord astrocytes [27, 74]. However, we did
not detect Fz2 in microglial cells, at least at the protein
level, although some reports have described low mRNA
expression levels in these cel ls in mice [75] .
Interestingly, we observed an evident increase in the
amount of Fz2+ astrocyte in ALS cases, which was
mainly identified in the transition between the GM of
the horns and the WM of the anterior funiculi.
Moreover, the increase in the amount of Fz2+ astrocytes
observed was inversely correlated with the amount of
preserved neurons, pointing to a connection between
the degree of neurodegeneration and the amount of
Fz2+ astrocytes in the affected regions. It should be
noted that the Pan-neuronal marker was initially choose
in order to do not miss potential changes in other neu-
ronal populations apart from MNs, but as the alterations
were observed at the ventral horn region, final studies
were carried out on that area. This increase in Fz2 ex-
pression by astrocytes has also been described in a
mouse model of ALS both in vivo and in primary cul-
tures of astrocytes from transgenic mice [30]. As has
been widely described [76–78], astrocytes are a key
component in the maintenance of CNS environment un-
der physiological conditions since, among other func-
tions, they control synaptic physiology and extracellular
ions and neurotransmitters levels, release neurotrophic
factors, modulate blood flow, and detoxify reactive ox-
ygen species. In ALS, aberrant astrocytic trophic sup-
port and/or secretion of neurotoxic cytokines and other
molecules have been proposed as relevant factors lead-
ing to MN death [52, 79, 80]. These observations, to-
gether with our results showing an increase in the
amount of Fz2+ astrocytes in ALS cases, within and
around damaged regions of the spinal cord, suggest that
this receptor may be involved in the pathological func-
tioning of astrocytes in human ALS. Otherwise, we did
not observe evident changes in the spatial Fz5 protein
expression pattern, apart from the fading of the signal
of this receptor in cells displaying a neuronal-like mor-
phology, probably due to the death of these cells in
ALS spinal cords. In contrast, in a recent publication
from our group in a mouse model of ALS, we showed
an increase in the immunoreactivity of Fz5 in neuronal
cells concomitant with the progression of the disease
[37]. This discrepancy might be explained by the exis-
tence of between-species differences, the influence of
the different experimental methods used, and/or the lim-
itations of the SOD1 transgenic model of ALS, which
represents only a portion of a more heterogeneous
population.
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To gain further insight into the involvement of Wnt family
of proteins in ALS pathogenesis, we subsequently assessed
the cellular protein expression pattern of Wnt5a as its
mRNA expression seems to be upregulated in ALS spinal
cords and, in different cells and circumstances, it acts as a
ligand of Fz2 to activate non-canonical Wnt signaling [74,
81–83].
In agreement with a previous study performed in mice
[30], we observed Wnt5a+ staining in neurons and astro-
cytes in the healthy human spinal cord. Although the
function of physiological Wnt5a protein expression in the
human spinal cord is poorly understood, it is interesting to
note that Wnt5a is involved, for instance, in regulating
synaptic physiology in hippocampal neurons [84, 85].
Interestingly, we show here that Wnt5a immunolabeling
is significantly increased in reactive astroglial located in
the affected areas of the ALS human spinal cord, where
we have previously observed the detailed changes in Fz2
expression, strongly indicating that Wnt5a protein expres-
sion is augmented in this cell type. In this line, it has
recently been reported that Wnt5a protein levels were sig-
nificantly higher in ALS mouse spinal cord, particularly at
the final stage of the disease, and that this increase in
Wnt5a expression was observed mainly in astrocytes
[30]. Although the potential functions of Wnt5a in the
progression of ALS are currently unknown, a recent report
showed that β-amyloid peptides induced the upregulation
of Wnt5a in mouse primary cortical mixed neuron/glia
cultures and that this increase in Wnt5a mediated the neu-
rotoxic effects induced by these noxious stimuli, since the
blockade of Wnt5a signaling using a specific antibody and
the modified Wnt5a-derived hexapeptide (Box5) displayed
a rescue effect on cell death, while the addition of recom-
binant Wnt5a or an agonistic molecule that mimics
Wnt5a-induced activities (Foxy5) potentiated neurotoxicity
[86]. Moreover, an important feature of ALS pathology, in
common with other neurodegenerative disorders, is the
reactive astrogliosis and microgliosis processes that have
been described both in human [58, 59, 87] and mouse
ALS spinal cord [88–90]. In mouse models, microglial
cells become activated early on, before MNs disappear,
and clinical disease onset [88, 89], whereas astrocytic ac-
tivation seems to take place concomitantly with a decrease
in neurons [91]. Interestingly, evidence from studies per-
formed in mice has shown that Wnt5a released by astro-
cytes plays a critical regulatory role in the proinflammato-
ry state of microglia [75]. In like manner, different studies
have demonstrated that Wnt5a acts as a proinflammatory
factor in microglial [75, 92] and astroglial cells [27], as
well as suggesting its potential contribution to the inflam-
matory response in several disease states [75, 93–96].
These observations, together with the results obtained in
the present study, point to a plausible proinflammatory
role of Wnt5a in ALS pathogenesis, in which the upreg-
ulated levels of this protein would trigger a proinflamma-
tory transformation of microglial and astroglial cells and
thus further promote neurotoxicity in ALS. As we previ-
ously stated, Fz2 is able to act as Wnt5a receptor in
different contexts [74, 81–83], suggesting that the potential
effects of Wnt5a in astroglial and neuronal cells in human
ALS cells may be, at least in part, mediated by Fz2 ex-
pression in these cell types. However, we did not find Fz2
expression in microglial cells. In this regard, it has been
reported that, apart from Fz2, Wnt5a can signal through
other Wnt receptors [97], and that primary mouse microg-
lia express different Wnt receptors, making these cells
responsive to recombinant purified Wnt5a [75, 98]. For
instance, Fz5 is expressed in microglia/macrophage cells
in the healthy and damaged spinal cord [23], while
Wnt5a-Fz5 interaction is involved in the regulation of
the inflammatory response in macrophages.
In summary, we demonstrate here for the first time that
the gene expression pattern of Wnt signaling is altered in
the anterior horn of human ALS spinal cord. Furthermore,
we demonstrate that two of the Wnt family members ana-
lyzed, Fz2 and Wnt5a, are also detected at the protein level
in the spinal cord of healthy controls and ALS cases. On
one hand, Fz2 was expressed by neurons and astrocytes in
the ventral horn of the spinal cord, and we observed an
increase in the amount of Fz2+ astrocytes in ALS subjects,
mainly located in the degeneration area within the ventral
horn. On the other hand, Wnt5a was located in neurons and
astrocytes, and we found a significant increase in the
amount of this Wnt5a+ astrocytes associated with ALS
pathology. Taken together, these results suggest that
Wnt5a and Fz2 signaling might play a critical role in harm-
ful processes associated with ALS such us neuronal death,
astrogliosis, and microgliosis. However, it should be noted
that we also found an increased expression of canonical
Wnt molecules such as Wnt3 and 4 in human ALS spinal
cord samples and that canonical Wnt signaling has been
shown to promote neuron survival in different neuropathol-
ogies [99]. Indeed, Riluzol, which is the only approved
treatment for ALS, is able to activate this Wnt signaling
pathway [100]. Therefore, we cannot discard the possibility
that, at least in part, the changes observed in the expression
of Wnt-related molecules might conform and endogenous
attempt to counteract neuronal death in ALS. In any case,
our findings provide novel insights into the pathogenesis of
ALS in human beings, suggesting the involvement of the
Wnt family of proteins in crucial neuropathological pro-
cesses in this neuropathology. Further research is needed
to elucidate the particular role of Wnt-related molecules in
ALS in order to identify novel therapeutic approaches to
the treatment of ALS and other neurodegenerative disorders
with shared neuropathological mechanisms.
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